The Intelligent Lab: How AI and Advanced Metabolomics are Redefining Scientific Discovery

The pace of scientific discovery is no longer governed solely by the physical limits of manual experimentation. We are currently witnessing a shift that is as transformative as the invention of the microscope itself. Artificial Intelligence (AI) and advanced metabolomics are reshaping how science is conducted, moving research from a “trial-and-error” model to a predictive, data-driven discipline. By combining high-resolution analytical hardware with machine learning, laboratories can now solve complex biological challenges – such as developing animal-free culture media – with unprecedented speed.

The complexity of the modern workflow

In the fast-evolving landscape of biopharmaceuticals and cell biology, the reliance on traditional methods often leads to significant hurdles. For decades, the industry has relied on fetal bovine serum (FBS) to supplement cell culture media, despite its high costs, ethical concerns, and inherent inconsistency.

Many lab teams find themselves buried under mountains of raw data from complex matrices, struggling to identify which specific molecular components actually drive performance.

When dealing with undefined raw ingredients, such as plant and microbial extracts, understanding chemical composition is critical to ensuring batch-to-batch reproducibility and process continuity when scaling.

From raw peaks to actionable insights

The challenge in modern labs isn’t a lack of data; it is the complexity of interpreting high-dimensional datasets. Manual analysis of thousands of formulations is no longer feasible. As regulatory requirements for biologics become more stringent, the demand for defined, reproducible, and regulatory-compliant media has grown.

Advanced metabolomics provides the molecular profiling required to qualify raw materials, while AI handles the broad combinatorial screening. This synergy allows researchers to tailor media composition to specific cell lines, improving yield and efficiency across the drug development lifecycle.

Optimising media with LC/Q-TOF

To solve the media development challenge, Chemetrix supports the implementation of untargeted metabolomic workflows. By utilising the Agilent 6545 LC/Q-TOF, labs can perform detailed molecular characterisation of both raw materials and finished formulations.

How Chemetrix assists:

Our specialists help your team establish metabolomic workflows that provide detailed molecular information for R&D. We assist in identifying “critical component targets” – biomarkers of performance – that become your QC benchmarks. By linking these molecular features to cellular outcomes, we help you replace inconsistent serums with precise, scalable,
animal-free alternatives.

Agilent 6545 LC/Q-TOF

Predictive productivity

Efficiency in the modern lab is increasingly driven by smart automation. The Agilent Infinity III LC Series is designed to address the operational risks that lead to downtime and lost samples through integrated AI-powered solutions.

How Chemetrix assists:

Chemetrix provides the technical expertise to integrate these platforms into your existing regulatory-ready environment. The Infinity III offers predictive analytics and real-time alerts to pre-empt operational failures. We assist in configuring these advanced informatics platforms so that your lab can handle complex workflows with greater precision. This shift to an automated, AI-enabled system allows your staff to focus on high-value data interpretation rather than routine manual monitoring.

Compressing development from years to months

The shift toward AI-guided development marks a new paradigm in biological optimisation. By continuously training algorithms with high-quality experimental data, each project makes the platform more intelligent. This iterative process has the power to compress development cycles that once took years into just a few months. When molecular characterisation is linked directly to cellular performance, the result is a more resilient supply chain and a faster time-to-market for novel therapies.

Optimising the path to discovery

The integration of AI and separation science is no longer a luxury; it is the foundation for the next generation of bioprocess innovation. At Chemetrix, we provide the local application expertise and technical support required to navigate these digital transformations.


Your action plan

Identify a workflow in your lab that currently relies on undefined ingredients or manual screening. Contact a Chemetrix specialist today for a workflow audit. We will help you leverage advanced metabolomics and AI-powered instrumentation to ensure your processes are reproducible, compliant, and ready for the future of biomanufacturing.

Analysis of Biopharmaceuticals: A Deeper Dive into Bioseparations

Ensuring the safety and efficacy of biotherapeutics from research to development, and then from manufacturing to quality control is essential to bring a product to market. Large molecules pose unique challenges for biotherapeutic analyses in that they often require running a panel of tests to ensure product efficacy and safety.

Industry efforts have evolved towards comprehensive analytical workflows that enable researchers to monitor critical quality attributes (CQAs) of highly complex and diverse biotherapeutic molecules.

Part 2: A Deeper Dive into Bioseparations

In the second session of this series we will discuss the range of bioseparation approaches used for characterization of CQAs in more detail. This includes solutions available for native (Size Exclusion, Ion Exchange, HIC) and reduced state (RP, HILIC) bioseparations for analysis of mAbs and other biotherapeutics.

 

Donna Potts
Biopharma Market Specialist EMEA IDO
Agilent Technologies

Donna is a Biopharma Market Specialist for Agilent Technologies; over the last decade she has been responsible for business development for Agilent analytical solutions in the Biopharma market space. Donna has worked extensively with biomolecules during her career, with a strong emphasis on Life Science and Biopharma applications using LC-MS.

After completing Postdoctoral Research at Boston University School of Medicine, she worked as an application specialist before becoming a Market Specialist in 2013. Donna holds a PhD in Analytical Chemistry from The University of Manchester, UK, where her studies focused on protein quantitation using mass spectrometry.

 

Cecilia Mazza
Product Specialist, EMEA IDO – Chemistries & Suppliers
Agilent Technologies

With more than 20 years of professional experience, Cecilia is presently the Product Specialist for columns and supplies at Agilent. Supporting distributors and laboratory users in the analysis and purification of small and large molecules, for a wide range of LC and GC applications as well as sample preparation.

Cecilia holds a Ph.D. in Chemical Engineering from Rensselaer Polytechnic Institute in US.

 

Register and watch on demand >

 

Analysis of Biopharmaceuticals: Introduction to Workflows

Ensuring the safety and efficacy of biotherapeutics from research to development, and then from manufacturing to quality control is essential to bring a product to market. Large molecules pose unique challenges for biotherapeutic analyses in that they often require running a panel of tests to ensure product efficacy and safety.

Industry efforts have evolved towards comprehensive analytical workflows that enable researchers to monitor critical quality attributes (CQAs) of highly complex and diverse biotherapeutic molecules.

Part 1: Introduction to Workflows

This presentation will provide an insight into the basics of the biopharma industry and introduce how analytical tools can be utilised as part of comprehensive workflows for characterisation of CQAs.

 

Donna Potts
Biopharma Market Specialist EMEA IDO
Agilent Technologies

Donna is a Biopharma Market Specialist for Agilent Technologies; over the last decade she has been responsible for business development for Agilent analytical solutions in the Biopharma market space. Donna has worked extensively with biomolecules during her career, with a strong emphasis on Life Science and Biopharma applications using LC-MS.

After completing Postdoctoral Research at Boston University School of Medicine, she worked as an application specialist before becoming a Market Specialist in 2013. Donna holds a PhD in Analytical Chemistry from The University of Manchester, UK, where her studies focused on protein quantitation using mass spectrometry.

 

Cecilia Mazza
Product Specialist, EMEA IDO – Chemistries & Suppliers
Agilent Technologies

With more than 20 years of professional experience, Cecilia is presently the Product Specialist for columns and supplies at Agilent. Supporting distributors and laboratory users in the analysis and purification of small and large molecules, for a wide range of LC and GC applications as well as sample preparation.

Cecilia holds a Ph.D. in Chemical Engineering from Rensselaer Polytechnic Institute in US.

 

Register and watch on demand >

 

InfinityLab OnLine HPLC Solution

In modern production of small molecule pharmaceuticals, biopharmaceuticals, and, in fact, ALL production batches, the reaction has to be closely monitored and potentially even controlled by, for instance, online reaction monitoring analytics. Therefore, connecting a UHPLC instrument by a sampling device to the reaction vessel can be helpful. The 1260 Infinity II Prime Online LC offers a combined UHPLC and integrated reactor sampling interface for automated reaction sample analysis with the Agilent 1260 Infinity II Online Sample Manager. This device enables the drawing of samples from a reactor and dilution/quenching prior to an injection.

This presentation will include a look at the hardware and software used for the Agilent OnLine LC system.  We will log into a live system to view the setup possibilities and review data acquired on the system.

 

Bob Giuffre
Application Engineer
Agilent Technologies, Inc.

 

Bob Giuffre has been working with HP/Agilent for almost thirty years as an Application Scientist for the HPLC product line. During that time Bob has worked on applications ranging from small molecule pharmaceutics to large molecule polymers, to monoclonal antibodies. Currently, Bob is working in the area of ultra-high pressure two-dimensional liquid chromatography as a means to increase peak capacity for complex formulations. Bob has authored a chapter on the use of Diode-Array Detection in Pharmaceuticals. He is currently writing a chapter on Troubleshooting Peptide and Proteins Analysis using LC-MS.

 

Register and watch on demand >